anti-CD3/anti-FLT3 bispecific T-cell engager (Pfizer/Allogene/Maverick)

N/A

Report date: 2026/03/19 16:53:50

Base Information

Drug Nameanti-CD3/anti-FLT3 bispecific T-cell engager (Pfizer/Allogene/Maverick)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncAllogene Therapeutics IncMaverick Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A